Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT01548482 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm
Lung Carcinoid Tumor
Recurrent Digestive System Neuroendocrine Tumor G1
Recurrent Renal Cell Carcinoma
Recurrent Uterine Corpus Sarcoma
Stage III Renal Cell Cancer
Stage IIIB Uterine Sarcoma
Stage IIIC Uterine Sarcoma
Stage IV Renal Cell Cancer
Stage IVA Uterine Sarcoma
Stage IVB Uterine Sarcoma

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Temsirolimus
BIOLOGICAL: Trebananib

Sponsor

National Cancer Institute (NCI)